Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
January 10, 2025 08:00 ET
|
Inozyme Pharma Inc.
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 27, 2024 08:30 ET
|
Inozyme Pharma Inc.
Inozyme's COO Matt Winton will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference
Inozyme Pharma to Present at Upcoming Investor Conferences
November 11, 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
November 05, 2024 08:30 ET
|
Inozyme Pharma Inc.
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric...
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
October 24, 2024 13:15 ET
|
Inozyme Pharma Inc.
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with...
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
October 17, 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
October 07, 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
September 26, 2024 08:00 ET
|
Inozyme Pharma Inc.
- Data underscore the urgent need for therapies that address the cardiovascular and musculoskeletal complications and long-term systemic effects of ENPP1 and ABCC6 Deficiencies in children - -...
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
August 29, 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
August 06, 2024 08:30 ET
|
Inozyme Pharma Inc.
Inozyme reported financial results for the second quarter ended June 30, 2024, and provided business highlights.